In the broader analysis of the five trials with a total of 21 947 participants, SGLT2 inhibitors reduced the risk of composite cardiovascular death or hospitalization for HF (HR 0.77 [95% CI 0.72–0.82]), cardiovascular death (0.87 [0.79–0.95]), first hospitalization for heart failure (HR 0.72 [95% CI 0.67–0.78]), and all-cause mortality (HR 0.92 [95% CI 0.86–0.99]). The gene discussed is SLC5A2; the disease is heart failure.